Eli Lilly and Company announced that retatrutide, its triple agonist, succeeded in two Phase 3 trials for obesity and type 2 diabetes, with results that position the drug as a meaningful revenue driver ahead of a planned Biologics License Application in the first quarter of 2027.
The 12 mg dose produced an average weight loss of 49.6 pounds, or 20.8 percent of body weight. The 9 mg dose delivered 45.4 pounds, or 19.1 percent of body weight. At 4 mg, patients lost an average of 29.8 pounds, or 12.7 percent of body weight.
On the diabetes front, retatrutide reduced A1C levels by an average of 1.6 percent. Forty percent of trial participants achieved an A1C below 5.7 percent, the key diabetes control threshold.
The dual efficacy distinguishes retatrutide from Eli Lilly's existing obesity drugs—Zepbound (tirzepatide-based) and Foundayo (orforglipron). The triple agonist mechanism targets three metabolic pathways simultaneously, a differentiated approach versus single or dual agonist competitors.
For Eli Lilly (LLY) investors, the Q1 2027 BLA submission is a concrete near-term catalyst. The company controls a widening share of the fast-growing obesity and diabetes market. Retatrutide's strength at the 12 mg dose—where efficacy stabilizes—suggests room for premium pricing and potential label expansion once approved. Watch for peak sales guidance in the next earnings call; analyst consensus will hinge on real-world adoption velocity and pricing relative to tirzepatide.
